Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1

Sponsor Class

INDUSTRY 6OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 1

Interventions

Cyclophosphamide 2064Radiotherapy 1984Cisplatin 1851Carboplatin 1557Gemcitabine 1452Paclitaxel 1320Bevacizumab 1316pembrolizumab 1235Docetaxel 1225Oxaliplatin 1181Capecitabine 1173Fluorouracil 1081Dexamethasone 979Magnetic Resonance Spectroscopy 967Nivolumab 936Rituximab 928Drug Therapy 911Surveys and Questionnaires 898Doxorubicin 845Etoposide 843Radiosurgery 814Blood Specimen Collection 814Irinotecan 783Cytarabine 743fludarabine 723Leucovorin 682Surgical Procedures, Operative 638Lenalidomide 618Biopsy 592fludarabine phosphate 568

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × taletrectinib × Clear all
NCT06214793 2025-05-01

Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC)

Case Comprehensive Cancer Center

Phase 2 Suspended
61 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡